We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pfizer to Buy Allergan in 160 Billion Dollar Deal

By HospiMedica International staff writers
Posted on 06 Dec 2015
In the largest ever deal in the health care sector, Pfizer (New York, NY, USA) will buy Botox maker Allergan (Dublin, Ireland), in a deal worth USD 160 billion.

The inversion acquisition, which would create the world's largest pharmaceutical conglomerate and shift Pfizer's headquarters to Ireland, would also be the biggest-ever instance of a US company reincorporating overseas to lower its taxes, from about 25% to about 17%–18% within the year. More...
The merger would also give Pfizer access to tens of billions of dollars that are outside the borders of the United States, allowing for more buybacks, dividend payments, and business development. The combined company would have annual sales of about USD 64 billion. The deal is expected to close in the second half of 2016.

The transaction was structured so that smaller, Ireland- based Allergan would buy Pfizer so as to avoid potential regulatory restrictions, although the combined company will be known as Pfizer and will continue to be led by CEO Ian Read. Allergan CEO Brent Saunders will become president and COO of the combined company, with oversight of all commercial businesses. The acquisition comes 18 months after an USD 118 billion bid to acquire AstraZeneca (London, United Kingdom) in a similar inversion failed due to stiff opposition from management and UK politicians.

“The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research, discover and deliver more medicines and therapies to more people around the world,” said Ian Read, Chairman and CEO of Pfizer. “Allergan's businesses align with and enhance Pfizer's businesses, creating best-in-class, sustainable, innovative and established businesses that are poised for growth.”

“The combination of Allergan and Pfizer is a highly strategic, value-enhancing transaction that brings together two biopharma powerhouses to change lives for the better,” said Brent Saunders, CEO of Allergan. “Joining forces with Pfizer matches our leading products in seven high-growth therapeutic areas and our robust R&D pipeline with Pfizer's leading innovative and established businesses, vast global footprint, and strength in discovery and development research to create a new biopharma leader.”

US President Barack Obama has called such inversion deals “unpatriotic” and has tried to crack down on the practice, and democratic presidential candidate Hillary Clinton has pledged to establish measures to prevent such deals. The merger was also criticized by rival democratic candidate Senator Bernie Sanders and Republican presidential candidate Donald Trump.

Related Links:

Pfizer 
Allergan
AstraZeneca



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Radiofrequency Generator
GX1
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie MellonImage: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie Mellon University)University)

Portable Artificial Lung Technology Could Reshape Care for Chronic Lung Disease

Chronic lung disease can leave patients dependent on prolonged mechanical ventilation or awaiting transplantation, both of which carry substantial morbidity and healthcare costs. Ventilatory support may... Read more

Surgical Techniques

view channel
Image Credit: 123RF

Needle-Free Intrauterine Anesthesia Technique Reduces Pain During IUD Insertion

Pain during intrauterine device (IUD) placement often deters women from choosing this long-acting contraception. Avoiding or undertreating procedural pain can reduce uptake and satisfaction with effective... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.